Lv2
178 积分 2021-03-05 加入
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
27天前
已完结
Lisaftoclax (APG-2575) is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
2个月前
已完结
Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax resistance in preclinical models of hematologic malignancy
2个月前
已完结
Effects of the combination of decitabine and homoharringtonine in SKM-1 and Kg-1a cells
3个月前
已完结
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
4个月前
已完结
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
4个月前
已完结
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
4个月前
已完结
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
4个月前
已完结
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
4个月前
已完结
皖公网安备34019202002308
